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A report on the Keystone Symposium ‘Epigenetics: Regulation
of Chromatin Structure in Development and Disease’,
Breckenridge, USA, 11-16 April 2007.
Epigenetics, which is the study of the information carried by
the genome that is not coded by DNA, is a rapidly expanding
field of study. A recent Keystone symposium on the regula-
tion of chromatin structure in development covered chroma-
tin structure, epigenetic memory mediated by the binding of
Polycomb group proteins and the hot topic of the role of
noncoding RNAs (ncRNAs) in heterochromatin formation,
DNA methylation targeting and gene silencing. Here we
focus on presentations that discussed the role of ncRNAs in
epigenetic regulation and the importance of intragenic
methylation in regulating transcription.
Noncoding RNAs in chromatin formation
One of the biggest questions in chromatin biology is how the
functional state of chromatin is established and maintained,
and there is now evidence that ncRNAs may be involved. The
role of an RNA interference (RNAi)-type mechanism in
heterochromatin formation was discussed by Danesh
Moazed (Harvard Medical School, Boston, USA), who
showed that known components of RNAi participate directly
in heterochromatin formation in the yeast Schizo-
saccharomyces pombe. He showed that transcripts from a
transgene inserted into a centromeric repeat gets processed
into small interfering RNAs (siRNAs) and bind to the
argonaute protein Ago1 and that this is a requirement for
efficient heterochromatic silencing. He proposed that the
nascent RNA transcripts from centromeric repeats may act
as a platform for heterochromatin assembly and these
heterochromatic transcripts are targeted to the exosome and
the RNAi pathway for degradation, in contrast to
euchromatic transcripts, which are translated into proteins.
Working with Tetrahymena, Yifan Liu (Rockefeller
University, New York, USA) showed that methylation of
lysine 27 on histone H3 (H3K27), a mark of repressive
heterochromatin, is dependent on the RNAi machinery, as
H3K27 methylation is abolished in deletion mutants of the
RNA processors dicer-like 1 (DCL1) and the piwi homolog
(TWI1) or the histone methyltransferase EZL1. This
indicates that ncRNAs may mediate the heritability of
histone modifications and heterochromatin formation,
although how they achieve this is still unknown.
The Xist ncRNA is thought to be instrumental in the cascade
of events that silence genes on one randomly chosen X
chromosome in female mammals. Sundeep Kalantry
(University of North Carolina, Chapel Hill, USA) described
studies analyzing the requirement for Xist in the initiation of
imprinted X-chromosome inactivation, which occurs during
pre-implantation development in mice. Using a GFP
transgene on the paternal X chromosome Kalantry showed
that Xist mutant embryos could still initiate stable imprinted
X inactivation and that the polycomb group protein Eed did
not accumulate on the mutant chromosome, suggesting that
X inactivation is initiated via an Xist-RNA independent
mechanism. The choice of X chromosome for inactivation
may not be as random as previously thought, according to
Barbara Panning (University of California, San Francisco,
USA), who suggested that the choice has already been made
in the embryonic stem cells (the cells of the inner cell mass)
and that the future inactive X may be marked by Polycomb
group proteins such as Eed. Panning used fluorescence in
situ hybridization to visualize the X-inactivation centre
(Xic) in paraformaldehyde-fixed female stem cells to show
that a high proportion of cells showed a single hybridization at
one allele and a double hybridization at the other allele (SD).
Upon differentiation, the ‘single’ allele cohybridized with the
Xist ncRNA and it was the switching between these single
and double states that underlies the random X inactivation.
It seems reasonable to assume that other ncRNAs may act
like Xist, in this case binding to autosomes to inhibit
transcription. Indeed, Takashi Nagano (Babraham Institute,
Cambridge, UK) showed that the Air ncRNA, which is an
antisense transcript from the imprinted Igf2r locus,
interacts with specific regions within the imprinted cluster
comprising the Igf2r, Slc22a2 and Slc22a3 genes. He
showed that Air RNA interacts with the paternally imprinted
Slc22a3 promoter in the placenta of embryonic mice at
11.5 days gestation, which correlates with the silencing of
this gene, while at 15.5 days this interaction decreases,
concomitant with gene activation. The mechanism by which
Air achieves silencing is unclear, but it may involve
restricting the nucleosomal mobility of the locus, thus
preventing contact with transcription factors, or it may
recruit other chromatin-modifying repressors.
John Rinn (Stanford University, Stanford, USA) presented
his recent work with the catch phrase “a fibroblast is not just
a fibroblast”. When he and his colleagues investigated the
expression of the HOX gene cluster in fibroblasts isolated
from different parts of the human body they discovered that
each fibroblast has a ‘postcode’ written into it by the
expression pattern of the HOX cluster ncRNAs. Rinn can
confidently describe the anatomical location of a fibroblast
on the basis of the expression pattern of as few as four HOX
genes, suggesting that adult fibroblasts do systematically
retain the embryonic gene-expression patterns that relate to
different positions along the embryonic developmental axis.
Interestingly, the diametrically opposite domains of hetero-
chromatin and euchromatin within the Hox gene cluster are
bordered by the gene for an ncRNA, called HOTAIR, which
physically interacts with the Polycomb group protein
complex PRC2 and is involved in suppressing transcription
of the HOXD locus. It is not yet clear whether the differences
in HOX gene expression between fibroblasts reflect the
microenvironment in which the cells reside, or if they result
in phenotypic differences; however, the implications are that
other cells in the body may also show similar anatomical
differences in gene expression.
Robert Kingston (Massachusetts General Hospital, Boston,
USA) addressed the significant question of what makes
gene-repressive states heritable. Kingston has identified
around 85,000 small RNAs (29-30 bp) from rat testis that
associate with the Argonaute protein RIWI (the rat homolog
of Drosophila PIWI) and have thus been designated PIWI-
associated RNAs (piRNAs). The genes encoding piRNAs are
typically located in conserved clusters and are expressed as
large transcripts from bidirectional promoters. As piRNAs
are not expressed in any cells other than the male germline,
they are thought to play a role in heritable gene silencing in
the male germline, possibly by guiding the cleavage of
repetitive transposon transcripts and inhibiting transposition.
Sarah Elgin (Washington University, St Louis, USA) reported
work investigating the role of ncRNAs in Drosophila by
looking at position-effect variegation. She and her colleagues
have found that mutations in the RNA processing proteins
piwi, aubergine and homeless all result in a loss of silencing.
Elgin reported that PIWI binds specifically to the hetero-
chromatin protein HP1a in a yeast two-hybrid assay, and
that a mutant transgene disrupting this interaction fails to
support gene silencing.
It is apparent that ncRNAs and RNAi components play a
significant role in gene silencing, but key questions remain.
Do the findings in model organisms hold true for humans?
Almost 50% of the human genome is composed of trans-
poson sequences and ncRNAs transcribed from these
elements might have a significant role in gene regulation.
Xist can cover the entire inactive X and Air ncRNA induces
silencing of a 500 kb imprinted locus. Thus, if ncRNAs can
silence chromatin locally, how far along a chromosome can
they extend and can other gene regions be silenced in a
similar manner? Answers to these questions may shed light
on how ubiquitous RNAi-mediated gene silencing really is.
Intragenic DNA methylation
While the effects of promoter methylation on chromatin
configuration and gene transcription have been well docu-
mented, several groups have recently turned their attention
to DNA methylation over the rest of the gene (gene-body
methylation). Both Steve Jacobsen (Howard Hughes
Medical Institute, University of California, Los Angeles,
USA) and Steven Henikoff (Fred Hutchinson Cancer
Research Center, Seattle, USA) reported chromatin immuno-
precipitation and DNA microarray (ChIP-on-chip) studies of
Arabidopsis showing that DNA methylation tends to lie
within the body of the gene and not at the 5′ or 3′ ends. Rob
Martienssen (Cold Spring Harbor Laboratory, Cold Spring
Harbor, USA) noted a similar trend, adding that
transposable elements are more often methylated through-
out. The role of RNAi components in heterochromatin
formation may also be linked to gene-body methylation, as
Martienssen shows that the RNAi components are also
essential for DNA methylation of transposons in Arabidopsis.
In humans, the role of RNAi components in heterochromatin
formation may also be linked to gene body methylation as
human genes contain transposons within intronic sequences.
There is a strong relationship between gene methylation and
transcription. From gene-expression analysis of met1 DNA
methyltransferase mutants, Henikoff concluded that gene-
body methylation impedes transcriptional elongation and is
most deleterious in short genes, where methylation extends
further into the 5′ and 3′ regions. Interestingly, moderately
expressed genes showed the highest levels of gene methy-
lation. Henikoff proposes a mechanism whereby intragenic
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methylation is caused by siRNAs aberrantly transcribed
from cryptic start sites that are exposed in the gene body as
chromatin structure is disrupted by the passage of RNA
polymerase II. Methylation is less pronounced in highly
expressed genes because the frequent passage of the
polymerase disrupts the production of these aberrant
transcripts. Conversely, in weakly expressed genes, methy-
lation is less pronounced as the chromatin is too condensed
to allow initiation from cryptic start sites. This may provide
an interesting mechanism for how a small change in gene
transcription could instigate a feedback loop leading to
further methylation and gene silencing.
An interesting experiment was described by Matthew Lorincz
(University of British Columbia, Vancouver, Canada) who
investigated the effects of intragenic DNA methylation on
transcription. He targeted reporter constructs to a specific
intergenic locus in murine erythroleukemia cells. The
reporters were either unmethylated or in vitro ‘patch’
methylated to 1 kb downstream of the transcription start
sites of the reporter genes. Whereas the unmethylated
reporters were consistently highly transcribed, a subset of
clones of the methylated reporters in which the methylation
had spread to within 300 bp of the transcription start site
showed drastically reduced transcription. Furthermore,
enrichment of H3K9 methylation in downstream methylated
regions, and altered upstream nucleosome positioning and
decreased H3K9/K14 acetylation in the promoters of the
methylated cassettes were observed.
Jeff Jeddeloh (Orion Genomics, St Louis, USA) concluded
from his methylation profiling of breast cancer that there are
at least two epigenetic types (epitypes) of this disease. One,
representing about 90% of breast cancer cases, was
detectable with Orion’s biomarkers, which pick up changes
in the methylation status of particular genes; however, none
of their biomarkers detected the remaining 10% of cases.
Many of the changes specific to breast cancer were hyper-
methylation (increased methylation) occurring not only in
promoters but also within the gene body. Surprisingly,
regions of the genome that did not include CpG islands had
substantial clinical power as DNA methylation biomarkers.
In the case of both lung and ovarian cancers, biomarkers
representing hypomethylation (a decrease in methylation
compared to normal) had considerable discriminatory
ability. There was very little overlap in the biomarker lists
(before or after validation) for these three cancers, and so it
is likely that each has disease-specific epigenetic pathways.
In humans, gene-body methylation may be associated with
the presence of repetitive transposon DNA sequences within
introns. Loss of methylation in these regions is likely to
permit transcription of the transposon sequences and
possibly allow the expression of cryptic transcripts or
antisense transcripts that might promote RNAi-mediated
gene silencing. It is possible that a loss of gene-body
methylation could be more common than hypermethylation
in cancers, given that there is a known overwhelming loss of
methylcytosine in cancer cell DNA. This will be an
interesting avenue for future research, and may also
challenge the paradigm that hypomethylation in cancer is
only associated with the activation of oncogenes. It is clear
that gene-body DNA methylation and ncRNA-mediated
silencing are closely related and it will be important to
explore the silencing role of gene-body-methylation further.
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